[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201900634VA - Chimeric antigen receptor - Google Patents

Chimeric antigen receptor

Info

Publication number
SG11201900634VA
SG11201900634VA SG11201900634VA SG11201900634VA SG11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA
Authority
SG
Singapore
Prior art keywords
international
tower
rule
temasek
tessa
Prior art date
Application number
SG11201900634VA
Inventor
John Edward CONNOLLY
Dang L Vu
Original Assignee
Tessa Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tessa Therapeutics Pte Ltd filed Critical Tessa Therapeutics Pte Ltd
Publication of SG11201900634VA publication Critical patent/SG11201900634VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIPO I PCT °Ens °nolo omm Oil mo 0II1111111 ow (10) International Publication Number WO 2018/019772 Al (51) International Patent Classification: A61K 39/00 (2006.01) Cl 2N 5/0783 (2010.01) C07K 16/30 (2006.01) (21) International Application Number: PCT/EP2017/068654 (22) International Filing Date: 24 July 2017 (24.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/366,729 26 July 2016 (26.07.2016) US 62/366,731 26 July 2016 (26.07.2016) US (71) Applicant: TESSA THERAPEUTICS PTE. LTD. [SG/SG]; 8 Temasek Boulevard #24-02, Suntec Tower Three, Singapore 038988 (SG). (71) Applicant (for LS only): RICHARD IAN CLEGG [GB/GB]; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (72) Inventors: CONNOLLY, John Edward; c/o Tessa Ther- apeutics Pte. Ltd., 8 Temasek Boulevard #24-02, Suntec Tower Three, Singapore 038988 (SG). VU, Dang L.; c/o Tessa Therapeutics Pte. Ltd., 8 Temasek Boulevard #24-02, Suntec Tower Three, Singapore 038988 (SG). (74) Agent: CLEGG, Richard et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: CHIMERIC ANTIGEN RECEPTOR (57) : Chimeric Antigen Receptors (CARs) comprising a costimulatory sequence which is, or which is derived from, the intracellular domain of CD226, or a fragment thereof, are disclosed. Also disclosed are compositions comprising such CARs, and uses and methods using the same. Figure 'IA W O 20 18/0 1977 2 Al Figure 113 [Continued on next page] WO 2018/019772 Al IMEDIMOM0101011MERIONIMOHMOHOMOIREM TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201900634VA 2016-07-26 2017-07-24 Chimeric antigen receptor SG11201900634VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662366731P 2016-07-26 2016-07-26
US201662366729P 2016-07-26 2016-07-26
PCT/EP2017/068654 WO2018019772A1 (en) 2016-07-26 2017-07-24 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
SG11201900634VA true SG11201900634VA (en) 2019-02-27

Family

ID=59569287

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900634VA SG11201900634VA (en) 2016-07-26 2017-07-24 Chimeric antigen receptor

Country Status (10)

Country Link
US (1) US20190262397A1 (en)
EP (1) EP3490589A1 (en)
JP (1) JP2019530431A (en)
KR (1) KR20190038567A (en)
CN (1) CN110035768A (en)
AU (1) AU2017301826A1 (en)
CA (1) CA3031846A1 (en)
SG (1) SG11201900634VA (en)
TW (1) TW201806969A (en)
WO (1) WO2018019772A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102529012B1 (en) * 2016-04-22 2023-05-09 크라제 메디컬 씨오 리미티드 Compositions and methods of cellular immunotherapy
JP7196094B2 (en) * 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific Antigen Binding Molecules for Costimulatory TNF Receptors
CN108913709A (en) * 2018-06-26 2018-11-30 山东兴瑞生物科技有限公司 For treating the preparation method of the nucleic acid of HCC, preparation method, CAR-T cell and cell with the nucleic acid
WO2020017479A1 (en) * 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 Anti-gpc3 single-chain antibody-containing car
AU2019354395A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
CN112300288B (en) * 2019-07-29 2022-08-02 济南赛尔生物科技股份有限公司 Chimeric antigen receptor CAR of CIK cell and application thereof
TW202124441A (en) * 2019-09-10 2021-07-01 美商賽特免疫治療公司 Bispecific antibody car cell immunotherapy
MX2022004080A (en) * 2019-10-07 2022-07-27 Fate Therapeutics Inc Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof.
CN110790842B (en) * 2019-11-25 2021-03-30 贵州康钦承平生物科技有限公司 FasL-CAR fusion protein, T cell for expressing fusion protein, and preparation method and application thereof
BR112022011957A2 (en) * 2019-12-20 2022-09-06 Medimmune Llc COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN 3
CN113087806B (en) * 2019-12-31 2022-09-06 华东师范大学 Novel CAR-T cells targeting multiple tumors, and preparation and methods thereof
KR20220155589A (en) * 2020-03-18 2022-11-23 주식회사 유틸렉스 GPC3 CAR-T cells secreting IL-18 and methods of making and using the same
CN115667500A (en) * 2020-03-18 2023-01-31 优特力克斯有限公司 GPC3 CAR-T cell compositions and methods of making and using the same
CN112225822B (en) * 2020-12-14 2021-03-23 北京基因启明生物科技有限公司 CAR-iNKT with high amplification, survival ability and tumor killing effect and application thereof
US20240366672A1 (en) * 2021-08-27 2024-11-07 Oricell Therapeutics Co., Ltd. Chimeric antigen receptor and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005137325A (en) 2003-05-31 2006-09-10 Микромет Аг (De) PHARMACEUTICAL COMPOSITION CONTAINING A DESIGN SPECIFIC TO ERS
US20050180979A1 (en) 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
EP2216046B1 (en) 2004-07-09 2014-03-12 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
RU2451030C2 (en) 2004-10-26 2012-05-20 Чугаи Сейяку Кабусики Кайся Anti-glypican 3-antibody having modified sugar chain
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
ATE512988T1 (en) 2007-04-04 2011-07-15 Sigma Tau Ind Farmaceuti ANTIBODIES TO EPCAM AND USES THEREOF
DK2178921T3 (en) 2007-07-17 2016-04-04 Squibb & Sons Llc Monoclonal antibodies to glypican 3
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011079283A1 (en) 2009-12-23 2011-06-30 Bioalliance C.V. Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
PT3012268T (en) 2010-09-08 2018-01-31 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Chimeric antigen receptors with an optimized hinge region
EP2998320B1 (en) 2011-04-19 2018-07-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2012153186A2 (en) 2011-05-06 2012-11-15 Kalgene Pharmaceuticals Inc. Monoclonal antibodies to epcam-icd and methods for detecting epithelial cancer cells
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013131001A1 (en) 2012-03-02 2013-09-06 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CN104140974B (en) 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
JP2017513818A (en) * 2014-03-15 2017-06-01 ノバルティス アーゲー Treatment of cancer using chimeric antigen receptors
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
EP3722316A1 (en) * 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
KR102612313B1 (en) * 2014-07-21 2023-12-12 노파르티스 아게 Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US20170209492A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
PL3183268T3 (en) * 2014-08-19 2020-09-07 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
DE20196219T1 (en) 2014-09-26 2021-10-28 Baylor College Of Medicine Glypican-3-Specific Chimeric Antigen Receptors for Adoptive Immunotherapy
US11459390B2 (en) * 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

Also Published As

Publication number Publication date
CN110035768A (en) 2019-07-19
KR20190038567A (en) 2019-04-08
JP2019530431A (en) 2019-10-24
WO2018019772A1 (en) 2018-02-01
TW201806969A (en) 2018-03-01
CA3031846A1 (en) 2018-02-01
US20190262397A1 (en) 2019-08-29
AU2017301826A1 (en) 2019-03-14
EP3490589A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
SG11201900634VA (en) Chimeric antigen receptor
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201811184UA (en) Lag -3 binding members
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201909541WA (en) Chimeric antibody/t-cell receptor constructs and uses thereof
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908088RA (en) Antibodies against pd-l1
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201906552WA (en) TGF-ß DECOY RECEPTOR
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201908056QA (en) Anti-par2 antibodies and uses thereof